Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 13;121(24):4861-6.
doi: 10.1182/blood-2012-12-475558. Epub 2013 May 2.

Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases

Luciano J Costa  1 , Ana C Xavier, Amy E Wahlquist, Elizabeth G Hill
Affiliations

Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases

Luciano J Costa et al. Blood. .

Abstract

It is unknown whether the high rates of cure reported for Burkitt lymphoma/leukemia (BL) patients treated with chemoimmunotherapy can be verified outside published series and clinical trials. We used the Surveillance Epidemiology and End Results (SEER) database to describe time trends in outcomes of BL in the United States. Cases were divided into 2 eras based on year of diagnosis, reflecting improvements in HIV management, BL treatment, and supportive care. There was a marked improvement in survival among BL cases diagnosed in the 2002-2008 era (n = 1922) relative to 1973-2001 (n = 1769) with 5-year relative survival estimates of 56% and 43%, respectively (P < .001). Five-year relative survival improved from 71% to 87% for ages 0 to 19 (n = 970), 35% to 60% for ages 20 to 39 (n = 897), 28% to 48% for ages 40 to 59 (n = 1047), and from 25% to 33% for ages ≥60 (n = 777). In multivariable analysis, the 2002-2008 era (HR = 0.76, P < .001) was associated with lower mortality. Conversely, older age, black race, and advanced stage were associated with higher mortality. More effective therapies are needed for older patients with BL, along with improved access to modern therapy for younger patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in estimated incidence of BL over the time span covered in the study.
Figure 2
Figure 2
Changes in overall survival for BL across the 2 eras for each specific age group.
Figure 3
Figure 3
Changes in overall survival for BL across the 2 eras for each specific race. API, Asian or Pacific Islander; IA/AN, Indian American/Alaska Native; Other, other unspecified.
Figure 4
Figure 4
Changes in overall survival for BL patients across the 2 eras and grouped by gender or summary stage.
See this image and copyright information in PMC

References

    1. Mead GM, Barrans SL, Qian W, et al. UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248–2260. - PMC - PubMed
    1. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461–2470. - PubMed
    1. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925–934. - PubMed
    1. Patte C, Auperin A, Michon J, et al. Société Française d’Oncologie Pédiatrique. The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–3379. - PubMed
    1. Gerrard M, Cairo MS, Weston C, et al. FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840–847. - PubMed

Publication types